The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Open accessThe DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Abstract
Human fungal pathogens are attributable to a significant economic burden and mortality worldwide. Antifungal treatments, although limited in number, play a pivotal role in decreasing mortality and morbidities posed by invasive fungal infections (IFIs). However, the recent emergence of multidrug-resistant Candida auris and Candida glabrata and acquiring invasive infections due to azole-resistant C. parapsilosis, C. tropicalis, and Aspergillus spp. in azole-naïve patients pose a serious health threat considering the limited number of systemic antifungals available to treat IFIs. Although advancing for major fungal pathogens, the understanding of fungal attributes contributing to antifungal resistance is just emerging for several clinically important MDR fungal pathogens. Further complicating the matter are the distinct differences in antifungal resistance mechanisms among various fungal species in which one or more mechanisms may contribute to the resistance phenotype. In this review, we attempt to summarize the burden of antifungal resistance for selected non-albicansCandida and clinically important Aspergillus species together with their phylogenetic placement on the tree of life. Moreover, we highlight the different molecular mechanisms between antifungal tolerance and resistance, and comprehensively discuss the molecular mechanisms of antifungal resistance in a species level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Phylogenetic tree of Candida species studied in the current review, i.e., C. glabrata, C. parapsilosis, C. tropicalis, and C. auris (highlighted in blue). This tree was constructed using maximum likelihood of 11,570 core genes based on 1000 replicates. Asterikes does not serve any specific defnitions. This figure was adopted permission from Munoz et al., 2018 [20].](https://figures.cochat.ai/paper-figures/3e30acfc216a4d828861bcc55bf652a6/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-1.jpg)

![Figure 3 Pdr1p contains four domains. Numerous GOF mutations (black bars) can cause azole resistance. Adopted the permission from Ferrari et al., 2009 [98].](https://figures.cochat.ai/paper-figures/bd4edb3b814e44a689549f07abf351f4/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-3.jpg)

![Figure 5 Whole-genome sequence analysis of the US C. auris (up to 2018) isolates reveals the existence of four major clades. Isolates representing all identified clades have been recovered from the U.S. The Iranian clade is not shown in this figure. Adopted the permission from Chow et al., 2018 [201].](https://figures.cochat.ai/paper-figures/6559288ef9344e4d9a16d7f660126cfa/the-quiet-and-underappreciated-rise-of-drug-resistant-invasive-fungal-pathogens-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“C. krusei is considered inherently resistant to fluconazole yet demonstrates variable susceptibility to both voriconazole and posaconazole.62,103,112”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fluconazole resistance has been reported in up to 75% of C. glabrata isolates in single center surveys, and resistance to the echinocandins ranges from 0% to 24% in larger studies.27,111–113”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to the echinocandins has remained relatively infrequent (0–3%) despite a higher baseline susceptible MIC cutoff value compared to the other Candida spp. due to a naturally occurring polymorphism in FKS1.62,103,112,120”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Phylogeny, identification and nomenclature of the genus Aspergillus
Samson, R. A., Visagie, C. M., Houbraken, J., Hong, S.-B., Hubka, V., Klaassen, C. H. W., Perrone, G., Seifert, K. A., Susca, A., Tanney, J. B., et al. (2014) · Studies in Mycology · doi:10.1016/j.simyco.2014.07.004 · Cited by 1,136
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Self-citationPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“At the institutional level, the prevalence of echinocandin resistance can vary significantly, reaching up to >13% at some centers [96].”
BackgroundSelf-citation
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“In pathogenic yeasts, ABC and MFS transporters are mainly overexpressed by GOF mutations in TAC1 and MRR1, respectively [19, 30, 46].”
BackgroundSelf-citationDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
“Using this standard, echinocandin resistance among Candida species is ideally suited for resistance assessment, as is azole resistance among Aspergillus, as there is a strong correlation between clinical resistance, MIC and specific mutations in target genes [133].”
BackgroundInfluentialSelf-citationAn Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
“Better knowledge of these resistance mechanisms would assist in developing alternative therapeutic strategies to combat refractory mycoses [80,81].”
Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272
Self-citationDaneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Self-citationAspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Self-citationMolecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
“Secondary resistance to echinocandins has been observed and linked to point mutations in the FKS1 gene that alter antifungal binding capacity [79].”
BackgroundHoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 186
Self-citationEpidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“62,103,112 In general, voriconazole has been considered the best oral option for C. krusei infections, however, recent population surveys have demonstrated emerging resistance rates to voriconazole, approximating 10% in some regions of the world.”
BackgroundFungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 119
Posteraro, B., Torelli, R., Vella, A., Leone, P. M., Angelis, G. D., Carolis, E. D., Ventura, G., Sanguinetti, M., & Fantoni, M. (2020) · Journal of Fungi · doi:10.3390/jof6030163 · Cited by 107
“This is surprising, particularly when thinking of Candida glabrata [15], a common fungal commensal living on mucosal surfaces, which is the second leading cause of bloodstream infection (candidemia) in some countries, including the USA, Asia and European countries [16,17].”
BackgroundInfluentialThomaz, D. Y., de Almeida, J. N., Sejas, O. N. E., Del Negro, G. M. B., Carvalho, G. O. M. H., Gimenes, V. M. F., de Souza, M. E. B., Arastehfar, A., Camargo, C. H., Motta, A. L., et al. (2021) · Journal of Fungi · doi:10.3390/jof7040259 · Cited by 95
“parapsilosis are mostly owing to horizontal transfer from contaminated environments [22], nonetheless, the environmental niche of ARCP isolates using the application of resolutive typing tools has yet to be determined.”
BackgroundSelf-citationWhat do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz, G., & Lorenz, A. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 85
Arastehfar, A., Hilmioğlu-Polat, S., Daneshnia, F., Pan, W., Hafez, A., Fang, W., Liao, W., Şahbudak-Bal, Z., Metin, D. Y., Júnior, J. N. D. A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.676177 · Cited by 83
Self-citationCandida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
“Key amino acid substitutions in ERG11 in C. parapsilosis are Y132F 28 followed by K143R, G458S, D421N and K128N 26,47,116 , all correlating with fluconazole resistance, with or without cross-resistance to voriconazole.”
BackgroundSelf-citationFrancesco, M. A. D. (2023) · Pathogens · doi:10.3390/pathogens12111305 · Cited by 81
“To date, the echinocandin resistance is rarely found in Aspergillus spp. [142].”
BackgroundArastehfar, A., Daneshnia, F., Cabrera, N., Penalva-Lopez, S., Sarathy, J., Zimmerman, M., Shor, E., & Perlin, D. S. (2023) · Nature Communications · doi:10.1038/s41467-023-36882-6 · Cited by 58
Self-citationSallam, N. M. A., Ali, E. F., Seleim, M. A. A., & Bagy, H. M. M. K. (2021) · Egyptian Journal of Biological Pest Control · doi:10.1186/s41938-021-00402-9 · Cited by 62
“…of Plant Pathology, Faculty of Agriculture, Assiut University, Assiut 71526, Egypt Full list of author information is available at the end of the article other methods for controlling of this disease are preferred, e.g., biological control and cultural practices (Arastehfar et al. 2019).”
BackgroundTrevijano-Contador, N., Torres-Cano, A., Carballo-González, C., Puig-Asensio, M., Martín-Gómez, M. T., Jiménez-Martínez, E., Romero, D., Nuvials, F. X., Olmos-Arenas, R., Moretó-Castellsagué, M. C., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac605 · Cited by 54
“Another strain harbored the G458S mutation, which has also been related 245 to azole resistance in Candida parapsilosis [4, 28].”
BackgroundHumans vs. Fungi: An Overview of Fungal Pathogens against Humans
Thambugala, K. M., Daranagama, D. A., Tennakoon, D. S., Jayatunga, D. P. W., Hongsanan, S., & Xie, N. (2024) · Pathogens · doi:10.3390/pathogens13050426 · Cited by 83
“; Table S2: A synopsis of human fungal pathogens and relevant disease conditions extracted from case studies.”
Díaz-García, J., Gómez, A., Alcalá, L., Reigadas, E., Sánchez‐Carrillo, C., Pérez‐Ayala, A., de la Pedrosa, E. G., González‐Romo, F., Amador, P. M., Cuétara, M. S., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-22 · Cited by 55
“tions involving the dominant Y132F substitution (5).”
Daneshnia, F., de Almeida, J. N., Arastehfar, A. A., Lombardi, L., Shor, E., Moreno, L., Mendes, A. V. A., Barberino, M. G., Thomaz, D. Y., Butler, G., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2117093 · Cited by 56
“Such overexpression is mainly driven by gain-of-function (GOF) mutations in transcription factors regulating CDR1, MDR1, and ERG11, namely TAC1, MRR1, andUPC2 [16].”
BackgroundSelf-citationHoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 45
“In C. auris and Candida species within the CTG-clade, the most clinically relevant mutations accountable for ECR are mapped to HS1 and HS2 of FKS1, while mutations occurring in HS1 of FKS1 and FKS2 are associated with ECR in C. glabrata [3].”
BackgroundInfluentialSelf-citationDesnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-20 · Cited by 44
“Despite reports of azole resistance acquired after treatment, in common and rare yeast species, and descriptions of an increasing percentage of resistant isolates (39), this phenomenon remains rare (1, 16, 40, 41) or has geographical specificity (42, 43) and seems to concern especially C.”
BackgroundBiofilm formation in clinically relevant filamentous fungi: a therapeutic challenge
Roudbary, M., Vahedi‐Shahandashti, R., dos Santos, A. L. S., Mohammadi, S. R., Aslani, P., Lass‐Flörl, C., & Rodrigues, C. F. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1950121 · Cited by 51
Self-citationArastehfar, A., Kargar, M. L., Mohammadi, S. R., Roudbary, M., Ghods, N., Haghighi, L., Daneshnia, F., Tavakoli, M., Jafarzadeh, J., Hedayati, M. T., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.655069 · Cited by 41
Self-citationArastehfar, A., Hilmioğlu-Polat, S., Daneshnia, F., Hafez, A., Salehi, M., Polat, F., Yaşar, M., Arslan, N., Hoşbul, T., Ünal, N., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.587278 · Cited by 40
Self-citationBeat the heat: correlates, compounds, and mechanisms involved in fungal thermotolerance
Mattoon, E. R., Casadevall, A., & Cordero, R. J. B. (2021) · Fungal Biology Reviews · doi:10.1016/j.fbr.2021.03.002 · Cited by 45
Antimicrobial Activity of the Peptide LfcinB15 against Candida albicans
Chang, C.-K., Kao, M., & Lan, C. (2021) · Journal of Fungi · doi:10.3390/jof7070519 · Cited by 40
“albicans has become a serious threat in the clinical setting [4].”
BackgroundSiopi, M., Papadopoulos, A., Spiliopoulou, A., Paliogianni, F., Abou‐Chakra, N., Arendrup, M. C., Damoulari, C., Tsioulos, G., Giannitsioti, E., Frantzeskaki, F. G., et al. (2022) · Journal of Fungi · doi:10.3390/jof8090931 · Cited by 39
Pfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 37
“Although antifungal resistance is a global concern (3, 4), fortunately at present, most”
BackgroundPolyene-Based Derivatives with Antifungal Activities
Ngece, K., Ntondini, T. L., Khwaza, V., Paca, A. M., & Aderibigbe, B. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081065 · Cited by 45
“Fungal failures resulting in antifungal resistance involve various subcellular mechanisms, including alteration of drug target, overexpression of efflux pumps and drug target, and gross chromosomal changes [6].”
BackgroundMechanisms of Azole Resistance and Trailing in Candida tropicalis Bloodstream Isolates
Chen, P., Chuang, Y., Wu, U., Sun, H., Wang, J., Sheng, W., Chen, Y., & Chang, S. (2021) · Journal of Fungi · doi:10.3390/jof7080612 · Cited by 36
“For example, genomic structure variations, either aneuploidy or copy number variations of drug resistant genes, also confer azole resistance and/or trailing [17,40].”
BackgroundEpidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018)
Arastehfar, A. A., Yazdanpanah, S., Bakhtiari, M., Fang, W., Pan, W., Mahmoudi, S., Pakshir, K., Daneshnia, F., Boekhout, T., İlkit, M., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myaa059 · Cited by 41
Self-citationda Silva Dantas, A., Nogueira, F., Lee, K. K., Walker, L. A., Edmondson, M., Brand, A. C., Lenardon, M. D., & Gow, N. A. R. (2021) · Journal of Cell Science · doi:10.1242/jcs.258889 · Cited by 31
“In addition, in the emerging pathogen Candida auris , echinocandin resistance occurs in 30% of all isolates from some parts of the world (Kordalewska et al., 2018; Arastehfar et al., 2020).”
Arastehfar, A. A., Ünal, N., Hoşbul, T., Özarslan, M. A., Karakoyun, A. S., Polat, F., Fuentes, D., Gümral, R., Turunç, T., Daneshnia, F., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac078 · Cited by 41
“Furthermore, emergence of drug-resistant Candida species, such as Candida auris, Candida parapsilosis, and Candida glabrata, imposes a growing threat due to limited options of antifungal therapy [2].”
BackgroundSelf-citationArastehfar, A. A., de Almeida, J. N., Perlin, D. S., İlkit, M., Boekhout, T., & Colombo, A. L. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1921695 · Cited by 35
“Although fungal species belonging to Candida, Cryptococcus and Aspergillus are the most prevalent among those causing invasive infections in humans (Arastehfar et al. 2020a, 2020b, 2020c), other fungal species have been increasingly identified and linked to fatal outcomes, among which Trichosporon…”
BackgroundSelf-citationEpidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study
Alobaid, K., Ahmad, S., Asadzadeh, M., Mokaddas, E. M., Al‐Sweih, N., Benwan, K. A., Alfouzan, W. A., Al‐Obaid, I., Jeragh, A., Al-Roomi, E., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080673 · Cited by 35
García‐Effrón, G. (2021) · Journal of Fungi · doi:10.3390/jof7030197 · Cited by 31
“The former was defined as the lack of inhibition of a microorganism in the infection site and it is related to different factors dependent on the drug, the patient, or both, rather than with the microorganism that causes the infection [9,10].”
BackgroundZhang, L., Xiao, M., Arastehfar, A. A., İlkit, M., Zou, J., Deng, Y., Xu, Y., Liao, W., Zhao, J., Fang, W., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.744502 · Cited by 30
Self-citationJospe‐Kaufman, M., Ben‐Zeev, E., Mottola, A., Dukhovny, A., Berman, J. G., Carmeli, S., & Fridman, M. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202314728 · Cited by 29
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 27
“…as well as those individuals suffering from severe respiratory viral infections (e.g., influenza and/or SARS-CoV-2) and the elderly (2–5, 48 Current antifungal agents cover most opportunistic fungal pathogens, including but not limited to C. albicans , A. fumigatus , and C. neoformans…”
BackgroundCandida parapsilosis Sensu Stricto Antifungal Resistance Mechanisms and Associated Epidemiology
Franconi, I., Rizzato, C., Poma, N. V., Tavanti, A., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9080798 · Cited by 29
“The same concept can be translated in yeast pathogens especially in Candida species [16,168,169].”
BackgroundCOVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Domán, M., & Bànyai, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919501 · Cited by 29
Approaches for identifying and measuring heteroresistance in azole-susceptible Candida isolates
Gautier, C., Maciel, E. I., & Ene, I. V. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04041-23 · Cited by 23
Coated Microneedle System for Delivery of Clotrimazole in Deep-Skin Mycoses
Jadach, B., Nowak, A., Długaszewska, J., Kordyl, O., Budnik, I., & Osmałek, T. Z. (2024) · Gels · doi:10.3390/gels10040264 · Cited by 22
Ünal, N., Spruijtenburg, B., Arastehfar, A. A., Gümral, R., de Groot, T., Meijer, E. F. J., Dağı, H. T., Bırıncı, A., Polat, S. H., Meis, J. F. G. M., et al. (2024) · Mycoses · doi:10.1111/myc.70000 · Cited by 25
“Unlike anti-biotics, there are only a limited number of antifungal drugs, namely, azoles, echinocandins and polyenes [4].”
Self-citationLogviniuk, D., Jaber, Q. Z., Dobrovetsky, R., Kozer, N., Księżopolska, E., Gabaldón, T., Carmeli, S., & Fridman, M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00269 · Cited by 24
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
“Genetic analysis and time‑kill assays may identify specific mutations associated with resistance, whereas tolerance may not be associated with stable genetic changes but rather transient stress responses (30,37).”
Tropical Medicinal Plant Extracts from Indonesia as Antifungal Agents against Candida Albicans
Geraldi, A., Wardana, A. P., Aminah, N. S., Kristanti, A. N., Sadila, A. Y., Wijaya, N. H., Wijaya, M. R. A., Diningrum, N. I. D., Hajar, V. R., & Manuhara, Y. S. W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2709274 · Cited by 33
“albicans due to extensive use of antifungal drugs in clinical settings [19,20].”
BackgroundSmall molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates
Alabi, P., Gautier, C., Murphy, T. P., Gu, X., Lepas, M., Aimanianda, V., Sello, J. K., & Ene, I. V. (2023) · mBio · doi:10.1128/mbio.00479-23 · Cited by 30
Moirangthem, R., Kumar, K., & Kaur, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02415-20 · Cited by 20
Pfaller, M. A., Carvalhaes, C. G., DeVries, S. D., Huband, M. D., & Castanheira, M. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115627 · Cited by 22
Arastehfar, A., Daneshnia, F., Floyd, D. J., Jeffries, N. E., Salehi, M., Perlin, D. S., Ilkit, M., Lass-Flöerl, C., & Mansour, M. K. (2024) · mBio · doi:10.1128/mbio.00072-24 · Cited by 19
“Notably, our analysis did not include the burden and ECR rate in cRPMI alone since we previously observed phenotypic resistance and extremely low levels of bona fide ECR colonies harboring mutations in the HS regions of the FKS1 and FKS2 genes (18).”
BackgroundInfluentialSelf-citationThe battle against fungi: lessons in antifungal stewardship from COVID 19 times
Kanj, S. S., Haddad, S. F., Meis, J. F. G. M., Verweij, P. E., Voß, A., Rautemaa‐Richardson, R., Levy-Hara, G., Chowdhary, A., Ghafur, A. K., Brüggemann, R. J. M., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106846 · Cited by 24
“This has been one of the most larming examples of collateral damage resulting from the COVID9 pandemic [15 , 16] .”
Najafzadeh, M. J., Shaban, T., Zarrinfar, H., Sedaghat, A., Hosseinikargar, N., Berenji, F., Jalali, M., Lackner, M., James, J. E., İlkit, M., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae031 · Cited by 20
Self-citationBinder, U., Arastehfar, A. A., Schnegg, L., Hörtnagl, C., Polat, S. H., Perlin, D. S., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040377 · Cited by 19
“Other determinants, such as overexpression of efflux pumps and ERG11 cooperatively contribute to azole resistance [23].”
BackgroundInfluentialSelf-citationBretagne, S., Desnos‐Ollivier, M., Sitbon, K., Lortholary, O., Che, D., Dromer, F., & YEASTS, P. O. T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.641965 · Cited by 19
“Therefore, it is possible that we did not observe emergence of resistance simply because, even if increasing, echinocandin prescription has not reached the level it has in the USA, especially as prophylaxis (35).”
BackgroundSingh, A. K., Kaur, A., & Chowdhary, A. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102365 · Cited by 21
A Comparative Transcriptome Between Anti-drug Sensitive and Resistant Candida auris in China
Zhou, W., Li, X., Lin, Y., Yan, W., Jiang, S., Huang, X., Yang, X., Qiao, D., & Li, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.708009 · Cited by 16
Wang, Q., Cai, X., Li, Y., Zhao, J., Liu, Z., Jiang, Y., Ling, M., Li, Y., Pan, S., Ai, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1006375 · Cited by 20
“The mechanism of echinocandin resistance involves mutations in FKS genes encoding subunits of glucan synthase (Arastehfar et al., 2020).”
BackgroundLim, H. J., Choi, M. J., Byun, S. A., Won, E. J., Park, J.-H., Choi, Y. J., Choi, H., Choi, H.-W., Kee, S., Kim, S. H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050515 · Cited by 19
“glabrata are being increasingly identified and have presented significant management challenges in recent years [4,9,18,19].”
BackgroundGabaldón, T. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00029-23 · Cited by 19
“An additional threat is posed by the increased incidence of drug resistance to one or several drugs (6), which is caused by either the increased incidence of some non-albicans species having intrinsic low levels of susceptibility or by secondary acquisition of resistance after drug exposure (7).”
Arastehfar, A. A., Marcet‐Houben, M., Daneshnia, F., Taj‐Aldeen, S. J., Batra, D. G., Lockhart, S. R., Shor, E., Gabaldón, T., & Perlin, D. S. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100133 · Cited by 18
Self-citationWon, E. J., Sung, H., & Kim, M. (2024) · Journal of Fungi · doi:10.3390/jof10030193 · Cited by 19
“Recently, candidemia caused by fluconazole-non-susceptible C. parapsilosis isolates has been increasingly reported worldwide, and outbreaks of fluconazole-resistant isolates have been reported from several countries during the pandemic [20–24].”
BackgroundPsychogenetic, genetic and epigenetic mechanisms in Candida auris: Role in drug resistance
Rabaan, A. A., Eljaaly, K., Alfouzan, W. A., Mutair, A. A., Alhumaid, S., Alfaraj, A. H., Aldawood, Y., Alsaleh, A. A., Albayat, H., Azmi, R. A., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.012 · Cited by 14
Nourrisson, C., Moniot, M., Lavergne, R., Robert, E., Bonnin, V., Hagen, F., Grenouillet, F., Cafarchia, C., Butler, G., Cassaing, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.09.021 · Cited by 14
Antifungal medicines in the terrestrial environment: Levels in biosolids from England and Wales
Martin, I., & Hart, A. J. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.161999 · Cited by 13
Phytotherapy: A Solution to Decrease Antifungal Resistance in the Dental Field
Cuenca-León, K., Pacheco-Quito, E.-M., Granda-Granda, Y., Vélez-León, E. M., & Castañeda, A. Z. (2022) · Biomolecules · doi:10.3390/biom12060789 · Cited by 25
Aşkun, T. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100869 · Cited by 16
Hartuis, S., Ourliac‐Garnier, I., Robert, E., Albassier, M., Duchesne, L., Beaufils, C., Kuhn, J., Pape, P. L., & Morio, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00022-24 · Cited by 26
“…has also been reported in several other opportunistic yeasts including C. albicans , Candida tropicalis , Candida orthopsilosis , and C. auris as well as in more distant species such as Diutina catenulata and Yarrowia lipolytica , showing its central role in fluconazole resistance (23, 36–38).”
BackgroundKoren, V., Ben‐Zeev, E., Voronov, I., & Fridman, M. (2024) · JACS Au · doi:10.1021/jacsau.4c00479 · Cited by 13
Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics
Singh, A., Singh, J., & Kumar, S. (2025) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3547 · Cited by 19
“This active transport results in lower drug concentration within the cell making the fungal cell resistant to the antifungal agent [47,79].”
InfluentialEmerging antifungal resistance in Candida parapsilosis: the end of the innocence
Guinea, J., Escribano, P., Cadeau, M., Lombardi, L., & Morio, F. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00173-5 · Cited by 18
“Compared to Tac1 and Mrr1,fewerthan 20 variants have been reported in Upc2, and none have been shown to alter fl uconazole susceptibility 68,71,88,94 .”
From the Ground to the Clinic: The Evolution and Adaptation of Fungi
Corrêa-Junior, D., Zamith‐Miranda, D., Frasés, S., & Nosanchuk, J. D. (2025) · Journal of Fungi · doi:10.3390/jof12010008 · Cited by 16
Microbiome of Clothing Items Worn for a Single Day in a Non-Healthcare Setting
Whitehead, K., Eppinger, J., Srinivasan, V., Ijaz, M. K., Nims, R. W., & McKinney, J. (2023) · Microbiology Research · doi:10.3390/microbiolres14030065 · Cited by 13
Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents
Zhang, J., Wang, Z., Gai, C., Yang, F., Yun, X., Jiang, B., Zou, Y., Meng, Q., Zhao, Q., & Chai, X. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117543 · Cited by 13
Melinte, V., Tudor, A. D., Bujoi, A. G., Radu, M. T., Văcăroiu, C. M., Cismaru, I. M., Holban, T. S., Mîrzan, L., Popescu, R., Ciupan, R. C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13040325 · Cited by 11
“In recent decades, multidrug-resistant fungal infections have attracted the attention of the international medical staff [1].”
BackgroundMiyazaki, T., Shimamura, S., Nagayoshi, Y., Nakayama, H., Morita, A., Tanaka, Y., Matsumoto, Y., Inamine, T., Nishikawa, H., Nakada, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56269-z · Cited by 11
Wang, Y., Zhao, X. Y., Cheng, J., Tang, X., Chen, X., Yu, H., & Li, S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.681488 · Cited by 12
“While antifungal drugs can be employed to treat Candida infections, mortality rates continue to rise (Ala-Houhala et al., 2019; Arastehfar et al., 2020).”
BackgroundLavergne, R., Albassier, M., Hardouin, J.-B., Álvarez, C., Pagniez, F., Morio, F., Pape, P. L., & Ourliac‐Garnier, I. (2022) · Microorganisms · doi:10.3390/microorganisms10010104 · Cited by 10
“They act by inhibiting the 14α-lanosterol demethylase, which has a key role in ergosterol biosynthesis [3].”
BackgroundFungAMR: A comprehensive portrait of antimicrobial resistance mutations in fungiPreprint
Bédard, C., Pageau, A., Fijarczyk, A., Mendoza-Salido, D., Alcañiz, A. J., Després, P. C., Durand, R., Plante, S., Alexander, E. M. M., Rouleau, F. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.07.617009 · Cited by 9
“AMR in human fungal pathogens poses a particularly daunting challenge due to the limited treatment options available 8,10 .”
BackgroundHuang, S., Lv, G., Song, Y., Zhao, J., Liu, J., Wang, L.-L., & Xiang, M.-J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1455145 · Cited by 8
Magrì, C., Carolis, E. D., Ivagnes, V., Pilato, V. D., Spruijtenburg, B., Marchese, A. E., Meijer, E. F. J., Chowdhary, A., & Sanguinetti, M. (2024) · Microorganisms · doi:10.3390/microorganisms12112153 · Cited by 9
Singampalli, A., Bandela, R., Kumar, P., Bakchi, B., Maddipatla, S., Bellapukonda, S. M., Nanduri, S., Shukla, R., Mishra, K., & Yaddanapudi, V. M. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500345 · Cited by 8
“Polyenes cause cell lysis by binding to fungal cell membrane ergosterol and echinocandins block (1,3)- β -d-glucan cell wall synthesis [5].”
Experimental evolution of drug resistance in human fungal pathogens
Gerstein, A. C., & Sethi, P. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101965 · Cited by 13
Byun, J., Won, E. J., Cho, H. W., Kim, D., Lee, H., Kim, S. H., Choi, M. J., Byun, S. A., Lee, G. Y., Kee, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00066-23 · Cited by 9
Jospe‐Kaufman, M., Ben‐Zeev, E., Mottola, A., Dukhovny, A., Berman, J. G., Carmeli, S., & Fridman, M. (2023) · Angewandte Chemie · doi:10.1002/ange.202314728 · Cited by 7
Li, Y., Hou, X., Li, R., Liao, K., Ma, L., Wang, X., Ji, P., Kong, H., Xia, Y., Ding, H., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03105-3 · Cited by 7
“The number of candidemia cases caused by C. glabrata exhibits a temporal increasing trend [4].”
BackgroundCai, L., Xue, X., Salehi, M., Perlin, D. S., Hoenigl, M., Liao, W., Pan, W., Arastehfar, A. A., & Fang, W. (2026) · iFungi · doi:10.26599/ifungi.2026.9670002 · Cited by 7
Self-citationInnovative and potential treatments for fungal central nervous system infections
Reguera-Gómez, M., Dores, M. R., & Martinez, L. R. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102397 · Cited by 9
Clinical impact of fluconazole-resistant Candida parapsilosis : a narrative review
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2544443 · Cited by 9
Arastehfar, A. A., Daneshnia, F., Hovhannisyan, H., Cabrera, N., İlkit, M., Desai, J. V., Gabaldón, T., Shor, E., & Perlin, D. S. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae035 · Cited by 7
“We selected 2 mutations in HS1-Fks1, S629P and R631G, and 2 mutations in HS1-Fks2, S663P and R665G.”
InfluentialSelf-citationKumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 7
Jampílek, J., & Kráľová, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99922-9.00013-1 · Cited by 6
Hwang, I. J., Kwon, Y. J., Lim, H. J., Hong, K. H., Lee, H., Yong, D., Won, E. J., Byun, S. A., Lee, G. Y., Kim, S. H., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00883-24 · Cited by 6
“However, despite the increasing number of cases of BSIs caused by FR C. glabrata globally (3, 5, 6, 8), the contribution of the clonal transmission of FR C. glabrata to the increases in BSI cases is unclear.”
BackgroundInfluentialYadav, A., Sah, S. K., Perlin, D. S., & Rustchenko, E. P. (2024) · Journal of Fungi · doi:10.3390/jof10030224 · Cited by 6
“Mechanisms that decrease drug susceptibility in the absence of FKS1 mutations are considered to be of critical importance as they allow transient survival in the presence of cidal ECNs and facilitate the evolution of classical clinical resistance [22,23].”
BackgroundSelf-citationDraft Genome Sequence of the Fluconazole-Resistant Yarrowia lipolytica Clinical Isolate CBS 18115
Lavergne, R., Barbier, P., Mobuchon, L., Banerjee, A., Prasad, R., & Morio, F. (2023) · Microbiology Resource Announcements · doi:10.1128/mra.01260-22 · Cited by 5
“Because this substitution has been associated with acquired fluconazole resistance in distant yeast species, we can expect its contribution to the elevated fluconazole MIC of our strain (11, 12).”
BackgroundBédard, C., Gagnon‐Arsenault, I., Boisvert, J., Plante, S., Dubé, A. K., Pageau, A., Fijarczyk, A., Sharma, J., Maroc, L., Shapiro, R. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571438 · Cited by 5
Balaeş, T., Mangalagiu, V., Antoci, V., Amăriucăi-Mantu, D., Diaconu, D., & Mangalagiu, I. I. (2025) · Pharmaceuticals · doi:10.3390/ph18040495 · Cited by 6
Metadata
- Authors
- Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S.
- Affiliations
- Hackensack Meridian Health (US)
- Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
- Westerdijk Fungal Biodiversity Institute (NL)
- Division of Mycology, University of Çukurova, 01330 Adana, Turkey
- Life Sciences Programme, Barcelona, Supercomputing Center (BSC-CNS), Jordi Girona, 08034 Barcelona, Spain
- Corresponding author
- Arastehfar, Amir
- Perlin, David S.
- ORCID
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-08-18
- Volume
- 6
- Issue
- 3
- Pages
- 138
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7557958
- OpenAlex
- W3070435984
- Semantic Scholar
- ffe1b3b580b5ee9de9aca8e5de0b85b315b7691d
- Cited by
- 145
- References
- 246
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 36 · 2023: 28 · 2022: 22 · 2021: 25 · 2020: 7
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UPCommons institutional repository (Universitat Politècnica de Catalunya) (acceptedVersion, cc-by)
- UvA-DARE (University of Amsterdam) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion, other-oa)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Astellas Pharma
- National Institutes of Health (AI109025)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- antifungal resistance, invasive fungal infections, Candida auris, Candida glabrata, Candida parapsilosis, Candida tropicalis, Aspergillus, multidrug resistance, azole resistance, antifungal tolerance, molecular mechanisms of resistance, non-albicans Candida, phylogenetic placement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.